BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 3, 2003
View Archived Issues
Opioid/NMDA receptor antagonist combinations result in superadditive antinociception in rats
Read More
Preclinical evidence for anxiolytic activity of substance P antagonists
Read More
APAZA completes first phase I trial
Read More
CA4P plus radioimmunotherapy tested in phase I/II trial for colorectal cancer
Read More
Salmedix initiates phase II/III program for SDX-105 for NHL
Read More
European CPMP hands down positive opinion for Zevalin
Read More
Dainippon and Takeda discontinue development of antidiabetic agent
Read More
Peninsula and Takeda enter licensing agreement for TAK-599
Read More
Improved BMD in hypogonadal men treated with testosterone gel
Read More
Lower incidence of fractures and improved bone quality in patients treated with risedronate
Read More
Escitalopram may be a better therapeutic option than venlafaxine XR in major depression
Read More
Oral gallium formulation reported to reach therapeutic serum levels in Paget's disease
Read More
Protective effects reported for CS-003 against bronchoconstriction in asthma
Read More
Kava presents new IL-12 and TNF-alpha production inhibitors and their use
Read More
Novel cPLA2 inhibitors prepared and tested at Wyeth
Read More
Synthesis and use of new CRF1 antagonists described in recent patent
Read More
Three series of alpha7 nAChR agonists presented in patents
Read More
New acetyl-CoA carboxylase inhibitors identified by Pfizer researchers
Read More
Novel PPAR modulators discovered by Lilly scientists
Read More
Schering-Plough acquires rights to palonosetron
Read More
Enrollment completed in second pivotal trial of E2F decoy
Read More
IND filed for Numax phase I trial
Read More
Phase III protocol for STR in multiple myeloma agreed under SPA
Read More
Roche and Protein Design Labs restructure Zenapax alliance
Read More
FDA issues another approvable letter to Lilly for duloxetine
Read More
TKT to report one-year phase I/II results for I2S at upcoming genetics meeting
Read More
CERA: a potent and long-acting erythropoietic agent
Read More